Overview
- GSK lifted its 2025 outlook to revenue growth of 6–7% and core operating profit growth of 9–11%, with core EPS now expected to rise 10–12%.
- Third-quarter revenue reached £8.5 billion and profit after tax was £2 billion, led by a 16% jump in specialty medicines and a 13% increase for shingles vaccine Shingrix.
- Management said the guidance incorporates tariffs announced so far and a modeled 15% European impact, and it has identified mitigation options.
- The company has not announced a pricing or tariff deal with the White House like AstraZeneca, with reports indicating discussions are underway.
- Royalty income of £800–£850 million tied to intellectual-property settlements supports the upgrade, as Emma Walmsley readies to hand the CEO role to Luke Miels in January and GSK pursues a $30 billion US investment plan.